Castle Biosciences (CSTL) Resumen de Acciones
Castle Biosciences, Inc. es una empresa de diagnóstico molecular que ofrece soluciones para el diagnóstico y tratamiento de cánceres dermatológicos, esófago de Barrett (EB), dermatitis atópica (DA) y melanoma uveal. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
CSTL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Castle Biosciences, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$24.16 |
| Máximo en las últimas 52 semanas | US$44.28 |
| Mínimo de 52 semanas | US$14.59 |
| Beta | 1.0 |
| Cambio en 1 mes | 19.31% |
| Variación en 3 meses | -3.55% |
| Cambio de 1 año | 46.07% |
| Variación en 3 años | 44.41% |
| Variación en 5 años | -64.88% |
| Variación desde la OPV | 12.90% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.
Actualización de narrativa • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.Recent updates
Actualización de narrativa • Jul 09
CSTL: Raised Fair Value Highlights Future Potential Of Quality Revenue Mix
Analysts have raised the fair value estimate for Castle Biosciences stock by $5 to $35, citing Street research that highlights quality revenue growth potential, solid gross margins, and a path toward sustainable profitability as key supports for higher price targets. Analyst Commentary Recent Street research on Castle Biosciences reflects a mix of optimism about the company’s revenue outlook and profitability path, alongside more cautious adjustments to price targets that highlight execution and valuation risks.Actualización de narrativa • Jun 25
CSTL: Test Volume Execution And Profit Path Will Underpin Upside Potential
Analysts have updated their price outlook on Castle Biosciences to reflect a $44.0 target, with the shift framed by recent Street research that highlights both reduced targets from some firms in the $35 to $40 range and continued emphasis on revenue growth potential, profit prospects and a solid balance sheet. Analyst Commentary Recent Street research on Castle Biosciences presents a mix of optimism around growth and profitability alongside more cautious revisions to price targets, giving you a fuller picture of how expectations are being reset.Actualización de narrativa • Jun 08
CSTL: Test Volume Execution And 2026 Guidance Will Underpin Upside Potential
Analysts have trimmed the price target on Castle Biosciences to $44.00 from $45.88, reflecting recent target reductions from multiple firms, even as they point to what they describe as solid test volume trends and ongoing upside potential in the stock. Analyst Commentary Recent Street commentary on Castle Biosciences points to a mixed setup, with target cuts clustered in the mid US$30s to low US$40s range and a focus on how execution in core tests might support that valuation.Actualización de narrativa • May 24
CSTL: 2026 Clinical Data And Guidance Will Support Upside Potential
Narrative Update: Castle Biosciences The updated analyst price target for Castle Biosciences shifts from $47.25 to $45.88 as analysts factor in the recent cuts in Street targets, along with views that solid Q1 volume growth in TissueCypher and DecisionDx-Melanoma still supports potential upside over time. Analyst Commentary Recent Street research on Castle Biosciences highlights a mix of optimism around execution and caution reflected in lower price targets.Actualización de narrativa • Apr 22
CSTL: 2026 Clinical Data And Guidance Will Support Higher Confidence
Analysts have trimmed their modeled fair value for Castle Biosciences to $47.25 from $48.50 as they recalibrate long term revenue growth, profit margin, and future P/E assumptions following a mix of recent price target increases and a reduction from different research firms. Analyst Commentary Bullish Takeaways Bullish analysts who raised their price targets highlight room for upside in their models, which typically reflects confidence in the company’s ability to execute on its current pipeline and commercial plans.Actualización de narrativa • Apr 04
CSTL: Preliminary 2025 Update Will Support Higher Confidence In 2026 Revenue
Analysts have lifted their price targets on Castle Biosciences by up to $17, reflecting updated models that now reference 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent price target changes cluster around updated 2026 revenue frameworks and the company’s preliminary 2025 revenue disclosure.Seeking Alpha • Mar 30
Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside
Summary Castle Biosciences, Inc. is positioned as a leader in precision cancer diagnostics, notably with DecisionDx-Melanoma, offering scalable, clinically validated solutions. CSTL reported strong Q4/FY2025 revenue growth and robust cash reserves but faces a projected EPS decline in 2026 as it invests aggressively in growth and commercialization. DecisionDx-Melanoma stands out as a de-risked, durable growth driver with high clinical utility, workflow integration, and payer support, targeting a large and growing melanoma market. I assign CSTL a conviction rating of 3/5, initiating a pilot position near technical support, with plans to build exposure as the market digests 2026 earnings and product adoption. Read the full article on Seeking AlphaActualización de narrativa • Mar 20
CSTL: Preliminary 2025 Revenue Signals Stronger Confidence In 2026 Outlook
Analysts have lifted their price targets on Castle Biosciences by amounts ranging up to $17, pointing to updated revenue estimates through 2026 and recent preliminary 2025 revenue disclosures as key drivers of their revised outlooks. Analyst Commentary Recent research notes focus on how preliminary 2025 revenue disclosures and updated 2026 revenue estimates feed into Castle Biosciences' valuation, with several firms adjusting their price targets to reflect these updated assumptions.Actualización de narrativa • Mar 06
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have modestly adjusted their fair value estimate for Castle Biosciences to $48.50, citing updated revenue growth and profit margin assumptions, as well as a slightly lower future P/E multiple, as reflected in recent price target increases from several firms. Analyst Commentary Recent research updates on Castle Biosciences have centered on revised revenue assumptions for 2025 and beyond, along with higher price targets that feed into the updated fair value estimate of $48.50.Actualización de narrativa • Feb 20
CSTL: Preliminary 2025 Revenue Outlook Will Support Higher 2026 Expectations
Analysts have raised their average price target on Castle Biosciences by $14, citing updated models that now rely more on 2026 revenue estimates and recent preliminary 2025 revenue disclosures. Analyst Commentary Recent research updates on Castle Biosciences focus heavily on how preliminary 2025 revenue information feeds into 2026 models, which in turn support higher price targets.Actualización de narrativa • Feb 05
CSTL: Preliminary 2025 Revenue Signals Will Support Extended 2026 Upside Potential
Narrative Update The updated analyst price target for Castle Biosciences moves from $46.00 to about $48.57. Analysts point to refreshed assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change.Actualización de narrativa • Jan 21
CSTL: Extended 2026 Revenue View And Test Adoption Will Support Upside
Narrative Update: Castle Biosciences Analysts have lifted their fair value estimate for Castle Biosciences from US$42.50 to US$46.00, citing updated modeling that now anchors price targets on 2026 revenue expectations following preliminary 2025 revenue disclosures. Analyst Commentary Recent Street commentary around Castle Biosciences is centering on how the preliminary 2025 revenue update reshapes expectations and valuation anchors out to 2026.Actualización de narrativa • Jan 06
CSTL: Dermatology Test Adoption And New Launches Will Support Balanced Outlook
Analysts have lifted their price target on Castle Biosciences from US$38.75 to US$42.50, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News New data from a prospective multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM and PRAME for uveal melanoma outcomes was published in Nature Communications, with DecisionDx-UM described as widely adopted in the U.S. standard of care and included in AJCC and NCCN guidelines (Key Developments).Actualización de narrativa • Dec 13
CSTL: Broader Dermatology Test Adoption Will Support Balanced Long-Term Outlook
Analysts have raised their price target on Castle Biosciences to approximately 38.75 dollars from about 35.63 dollars, citing stronger expectations for revenue growth and slightly improved profit margins, despite a modestly higher discount rate and lower projected future P E multiple. What's in the News An independent expert consensus panel endorsed Castle Biosciences DecisionDx-Melanoma test as providing robust, clinically validated prognostic information that improves melanoma risk stratification and supports more precise treatment decisions (expert consensus paper).Artículo de análisis • Nov 06
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up
Despite an already strong run, Castle Biosciences, Inc. ( NASDAQ:CSTL ) shares have been powering on, with a gain of...Artículo de análisis • Aug 24
What Castle Biosciences, Inc.'s (NASDAQ:CSTL) 30% Share Price Gain Is Not Telling You
The Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has done very well over the last month, posting an excellent...Artículo de análisis • Jun 28
Is Castle Biosciences (NASDAQ:CSTL) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • May 23
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
Unfortunately for some shareholders, the Castle Biosciences, Inc. ( NASDAQ:CSTL ) share price has dived 28% in the last...Artículo de análisis • Apr 16
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
While Castle Biosciences, Inc. ( NASDAQ:CSTL ) might not have the largest market cap around , it saw a double-digit...Seeking Alpha • Apr 14
Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Summary Castle Biosciences offers diverse diagnostic tests, with DecisionDx-Melanoma being a key revenue driver, but faces potential Medicare reimbursement loss for DecisionDx-SCC in 2025. The company is expanding its portfolio with TissueCypher and IDgenetix, showing strong growth, though IDgenetix faces uncertain long-term performance. Castle is well capitalized with $293 million in cash, providing a strong runway, but continues to burn cash, mainly on general and admin expenses. Trading near 52-week lows, CSTL stock presents a good entry point, but investors should watch for clarity on the SCC non-coverage issue. Read the full article on Seeking AlphaArtículo de análisis • Feb 25
Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...
Nueva narrativa • Feb 13
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Artículo de análisis • Dec 12
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Oct 15
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Key Insights The projected fair value for Castle Biosciences is US$66.66 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Aug 16
Castle Biosciences: Inflection Into Profitability
Summary Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. Castle Biosciences faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field. Read the full article on Seeking AlphaArtículo de análisis • Aug 11
Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Celebrations may be in order for Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders, with the analysts delivering a...Artículo de análisis • Aug 08
Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders of Castle Biosciences, Inc. ( NASDAQ:CSTL ) will be pleased this week, given that the stock price is up...Artículo de análisis • Aug 04
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders are no doubt pleased to see that the share price has bounced 28...Artículo de análisis • Jul 12
Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Apr 30
Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
When close to half the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S...Rentabilidad de los accionistas
| CSTL | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 1.9% | -0.4% | -2.0% |
| 1Y | 46.1% | 39.0% | 17.2% |
Rentabilidad vs. Industria: CSTL superó a la industria US Healthcare, que obtuvo un rendimiento del 39% el año pasado.
Rentabilidad vs. Mercado: CSTL superó al mercado US, que obtuvo un rendimiento del 17.2% el año pasado.
Volatilidad de los precios
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 9.4% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: CSTL no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CSTL (9%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 942 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc, una empresa de diagnóstico molecular, ofrece soluciones de pruebas para el diagnóstico y tratamiento de cánceres dermatológicos, esófago de Barrett (EB), dermatitis atópica (DA) y melanoma uveal. La empresa ofrece DecisionDx-Melanoma, una prueba de perfil de expresión génica (GEP) de estratificación del riesgo que predice la probabilidad de un ganglio linfático centinela positivo y el riesgo de metástasis en pacientes con melanoma cutáneo invasivo; TissueCypher, una prueba espacialómica de estratificación del riesgo para predecir el desarrollo futuro de displasia de alto grado y/o cáncer de esófago en pacientes con BE no displásica, displasia indefinida y displasia de bajo grado; AdvanceAD-Tx, una prueba de BPA no invasiva diseñada para guiar la selección del tratamiento sistémico en pacientes mayores de 12 años con EA moderada o grave; DecisionDx-SCC, una prueba de BPA para el carcinoma escamoso cutáneo; y MyPath Melanoma, una prueba de BPA diagnóstica para pacientes con lesiones melanocíticas de difícil diagnóstico. También ofrece DecisionDx-UM, una prueba GEP de estratificación del riesgo que predice el riesgo de metástasis en pacientes con melanoma uveal.
Resumen de fundamentos de Castle Biosciences, Inc.
| Estadísticas fundamentales de CSTL | |
|---|---|
| Capitalización bursátil | US$734.89m |
| Beneficios(TTM) | -US$12.83m |
| Ingresos (TTM) | US$339.92m |
2.2x
Ratio precio-ventas (PS)-57.1x
Ratio precio-beneficio (PE)¿Está CSTL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CSTL | |
|---|---|
| Ingresos | US$339.92m |
| Coste de los ingresos | US$75.18m |
| Beneficio bruto | US$264.74m |
| Otros gastos | US$277.57m |
| Beneficios | -US$12.83m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 30, 2026
| Beneficios por acción (BPA) | -0.42 |
| Margen bruto | 77.88% |
| Margen de beneficio neto | -3.78% |
| Ratio deuda/patrimonio | 2.2% |
¿Cómo se ha desempeñado CSTL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/17 12:06 |
| Precio de las acciones al final del día | 2026/07/17 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Castle Biosciences, Inc. está cubierta por 11 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |